Pfizer Inc. (NYSE:PFE) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 3.5% during the fourth quarter, HoldingsChannel reports. The firm owned 39,402,619 shares of the biopharmaceutical company’s stock after purchasing an additional 1,333,740 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Pfizer were worth $1,045,351,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Tallon Kerry Patrick purchased a new position in Pfizer during the fourth quarter worth about $509,000. Merit Financial Group LLC boosted its stake in shares of Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock valued at $3,395,000 after buying an additional 48,397 shares in the last quarter. Ameritas Advisory Services LLC grew its holdings in Pfizer by 3.6% during the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company’s stock worth $2,016,000 after acquiring an additional 2,633 shares during the period. Aaron Wealth Advisors LLC lifted its holdings in Pfizer by 18.5% in the fourth quarter. Aaron Wealth Advisors LLC now owns 19,645 shares of the biopharmaceutical company’s stock valued at $521,000 after acquiring an additional 3,069 shares during the period. Finally, Cascade Investment Group Inc. boosted its position in shares of Pfizer by 4.2% during the 4th quarter. Cascade Investment Group Inc. now owns 32,007 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 1,277 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on PFE shares. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.01 on Tuesday. The business has a fifty day simple moving average of $23.60 and a 200-day simple moving average of $25.28. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a market cap of $130.82 billion, a P/E ratio of 16.32, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter last year, the business earned $0.82 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.48%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.